[go: up one dir, main page]

ZA955724B - Process for synthesis of substituted sulphoxides - Google Patents

Process for synthesis of substituted sulphoxides

Info

Publication number
ZA955724B
ZA955724B ZA955724A ZA955724A ZA955724B ZA 955724 B ZA955724 B ZA 955724B ZA 955724 A ZA955724 A ZA 955724A ZA 955724 A ZA955724 A ZA 955724A ZA 955724 B ZA955724 B ZA 955724B
Authority
ZA
South Africa
Prior art keywords
synthesis
sulphoxides
substituted
substituted sulphoxides
Prior art date
Application number
ZA955724A
Other languages
English (en)
Inventor
Erik Magnus Larsson
Urban Jan Stenhede
Hendrik Soerensen
Per Oskar Sverker Von Unge
Hanna Kristina Cotton
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20394753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA955724(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Publication of ZA955724B publication Critical patent/ZA955724B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA955724A 1994-07-15 1995-07-10 Process for synthesis of substituted sulphoxides ZA955724B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9402510A SE504459C2 (sv) 1994-07-15 1994-07-15 Förfarande för framställning av substituerade sulfoxider

Publications (1)

Publication Number Publication Date
ZA955724B true ZA955724B (en) 1996-01-15

Family

ID=20394753

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA955724A ZA955724B (en) 1994-07-15 1995-07-10 Process for synthesis of substituted sulphoxides

Country Status (42)

Country Link
US (1) US5948789A (sv)
EP (1) EP0773940B2 (sv)
JP (1) JP3795917B2 (sv)
KR (1) KR100356252B1 (sv)
CN (1) CN1070489C (sv)
AR (1) AR003443A1 (sv)
AT (1) ATE242233T1 (sv)
AU (1) AU688074B2 (sv)
BR (1) BR9508292A (sv)
CA (1) CA2193994C (sv)
CZ (1) CZ297987B6 (sv)
DE (1) DE69530987T3 (sv)
DK (1) DK0773940T4 (sv)
DZ (1) DZ1911A1 (sv)
EE (1) EE03354B1 (sv)
EG (1) EG24534A (sv)
ES (1) ES2199998T5 (sv)
FI (2) FI117830B (sv)
HK (1) HK1008331A1 (sv)
HR (1) HRP950401B1 (sv)
HU (1) HU226361B1 (sv)
IL (1) IL114477A (sv)
IS (1) IS1772B (sv)
MA (1) MA23611A1 (sv)
MX (1) MX9700358A (sv)
MY (1) MY113180A (sv)
NO (1) NO312101B1 (sv)
NZ (1) NZ289959A (sv)
PL (1) PL186342B1 (sv)
PT (1) PT773940E (sv)
RU (1) RU2157806C2 (sv)
SA (1) SA95160294B1 (sv)
SE (1) SE504459C2 (sv)
SI (1) SI0773940T2 (sv)
SK (1) SK284059B6 (sv)
TN (1) TNSN95081A1 (sv)
TR (1) TR199500861A2 (sv)
TW (1) TW372971B (sv)
UA (1) UA47409C2 (sv)
WO (1) WO1996002535A1 (sv)
YU (1) YU49475B (sv)
ZA (1) ZA955724B (sv)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
AU746706B2 (en) * 1997-07-03 2002-05-02 Du Pont Pharmaceuticals Company Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704183D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New process
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
CA2320963A1 (en) * 1998-01-30 1999-08-05 Sepracor, Inc. R-lansoprazole compositions and methods
AU3967399A (en) * 1998-04-30 1999-11-16 Sepracor, Inc. S-rabeprazole compositions and methods
WO1999055157A1 (en) * 1998-04-30 1999-11-04 Sepracor Inc. R-rabeprazole compositions and methods
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
CN1087739C (zh) * 1998-12-28 2002-07-17 中国科学院成都有机化学研究所 光学纯的苯并咪唑类抗消化性溃疡药物的包结拆分制备法
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
WO2001002389A1 (fr) * 1999-06-30 2001-01-11 Takeda Chemical Industries, Ltd. Cristaux de composes benzimidazole
AU6727700A (en) * 1999-08-25 2001-03-19 Takeda Chemical Industries Ltd. Process for the preparation of optically active sulfoxide derivatives
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
ES2273829T3 (es) * 2000-04-28 2007-05-16 Takeda Pharmaceutical Company Limited Procedimiento para producir derivado de sulfoxido opticamente activo.
KR100869677B1 (ko) 2000-05-15 2008-11-21 다케다 야쿠힌 고교 가부시키가이샤 결정의 제조방법
CA2762960C (en) 2000-05-15 2014-07-22 Takeda Pharmaceutical Company Limited Recrystallization processes for obtaining anhydrous optically active lansoprazole
ATE342263T1 (de) 2000-08-04 2006-11-15 Takeda Pharmaceutical Salze von benzimidazol-derivaten und deren verwendung
ATE511508T1 (de) * 2000-12-01 2011-06-15 Takeda Pharmaceutical Verfahren zur kristallisation von (r)- oder (s)- lansoprazol
AU2002338655A1 (en) * 2001-04-13 2002-10-28 Aspinterm Llc Methods of preparing sulfinamide and sulfoxides
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
US20040006111A1 (en) * 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
DE60314105T2 (de) * 2002-03-05 2008-01-24 Astrazeneca Ab Alkylammoniumsalze von omeprazol und esomeprazol
AU2003262375A1 (en) * 2002-04-22 2003-11-03 Sun Pharmaceutical Industries Limited Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts
WO2004002982A2 (en) * 2002-06-27 2004-01-08 Dr. Reddy's Laboratories Limited A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
ES2534713T3 (es) 2002-10-16 2015-04-27 Takeda Pharmaceutical Company Limited Preparaciones sólidas estables
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
BR0315574A (pt) 2002-10-22 2005-09-20 Ranbaxy Lab Ltd Forma amorfa de esomeprazol, composição farmacêutica contendo o mesmo e processo para sua preparação
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
RS52667B (en) * 2002-12-06 2013-06-28 Nycomed Gmbh PROCEDURE FOR PREPARING OPTICALLY CLEAN UNITS
BR0316702A (pt) 2002-12-06 2005-10-18 Altana Pharma Ag xprocesso para preparação de (s)-pantoprazol
FR2848555B1 (fr) 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
AU2003288576A1 (en) * 2002-12-16 2004-07-09 Ranbaxy Laboratories Limited Rabeprazole calcium
EP1572680A2 (en) 2002-12-19 2005-09-14 Eva Pharmaceutical Industries Ltd. Solid states of pantoprazole sodium, known pantoprazole sodium hydrates, processes for their preparation.
EP1583507A2 (en) * 2003-01-07 2005-10-12 Ranbaxy Laboratories Limited Magnesium salt of imidazole derivative
WO2004073654A2 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid
BRPI0407906A (pt) * 2003-02-28 2006-02-14 Ranbaxy Lab Ltd polimorfos de s-omeprazol
EP1601667A2 (en) * 2003-03-12 2005-12-07 Teva Pharmaceutical Industries Limited Crystalline and amorphous solids of pantoprazole and processes for their preparation
US7608625B2 (en) * 2003-03-13 2009-10-27 Eisai R & D Management Co., Ltd. Method for treating bruxism and bruxism-related diseases
FR2852956B1 (fr) * 2003-03-28 2006-08-04 Negma Gild Procede de preparation enantioselective de derives de sulfoxydes
JP2006523201A (ja) * 2003-03-28 2006-10-12 シデム ファーマ スルホキシド誘導体をエナンチオ選択的に調製する方法
CN1842525A (zh) * 2003-05-05 2006-10-04 兰贝克赛实验室有限公司 苯并咪唑衍生物的钡盐
EP1615913A2 (en) 2003-06-10 2006-01-18 Teva Pharmaceutical Industries Limited Process for preparing 2-(pyridinyl)methyl sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
SE0302382D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
WO2005054228A1 (en) * 2003-12-05 2005-06-16 Hetero Drugs Limited A process for the preparation of substitited pyridinylmethylsulfinyl- benzimidazole enantiomers
SE0400410D0 (sv) * 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
WO2005105786A1 (en) 2004-04-28 2005-11-10 Hetero Drugs Limited A process for preparing pyridinylmethyl-1h- benzimidazole compounds in enantiomerically enriched form or as single enantiomers
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ATE456566T1 (de) * 2004-05-28 2010-02-15 Hetero Drugs Ltd Neue stereoselektive synthese von benzimidazolsulfoxiden
BRPI0511515A (pt) * 2004-06-02 2007-12-26 Altana Pharma Ag processo para a preparação de compostos de piridin-2-ilmetilsulfinil-1h-benzimidazol
JP5563735B2 (ja) 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
EP1765806A1 (en) * 2004-06-24 2007-03-28 AstraZeneca AB New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt
US20080249134A1 (en) * 2004-06-24 2008-10-09 Ursula Hohlneicher New Esomeprazole Sodium Salt Crystal Modification
FR2876101B1 (fr) * 2004-10-05 2007-03-02 Sidem Pharma Sa Sa Procede de preparation enantioselective de derives de sulfoxydes
WO2006040635A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited Processes for the preparation of substituted sulfoxides
US7592111B2 (en) * 2004-11-05 2009-09-22 Xerox Corporation Imaging member
CN101098867B (zh) * 2005-03-25 2010-08-11 丽珠医药集团股份有限公司 取代的亚砜类化合物和其制备方法及用途
US20060217423A1 (en) * 2005-03-25 2006-09-28 Jingen Deng Substituted sulfoxide compounds, methods for preparing the same and use thereof
KR20080007508A (ko) * 2005-05-06 2008-01-21 그렌마크 파머수티칼스 엘티디. 에소메프라졸 스트론튬염, 그것의 제조방법 및 그것을함유하는 약제학적 조성물
US8247566B2 (en) * 2005-06-08 2012-08-21 Lek Pharmaceuticals D.D. Crystalline solvate of omeprazole sodium
US20070043085A1 (en) * 2005-08-19 2007-02-22 Glenmark Pharmaceuticals Limited Process for the preparation of amorphous form of neutral esomeprazole
EP1960384A4 (en) * 2005-12-05 2010-03-24 Astrazeneca Ab NOVEL PROCESS FOR THE PRODUCTION OF NON-SALINE ESOMEPRAZOLE
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
DE102005061720B3 (de) * 2005-12-22 2006-10-19 Ratiopharm Gmbh Enantioselektive Herstellung von Benzimidazolderivaten und ihren Salzen
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
CA2631459A1 (en) 2005-12-28 2007-07-05 Union Quimico Farmaceutica, S.A. A process for the preparation of the (s)-enantiomer of omeprazole
CN1810803B (zh) * 2006-02-17 2010-11-17 中国科学院上海有机化学研究所 高对映体选择性制备(s)-奥美拉唑的方法
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
US8063074B2 (en) * 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
US7786309B2 (en) * 2006-06-09 2010-08-31 Apotex Pharmachem Inc. Process for the preparation of esomeprazole and salts thereof
WO2008004245A1 (en) 2006-07-05 2008-01-10 Lupin Limited Process for the preparation of optically pure or optically enriched enantiomers of sulphoxide compounds
EP2054403A1 (en) 2006-08-08 2009-05-06 Jubilant Organosys Limited Process for producing sulphoxide compounds
JP2009196894A (ja) * 2006-10-13 2009-09-03 Eisai R & D Management Co Ltd スルフィニルベンズイミダゾール化合物またはその塩の製造方法
JP5492417B2 (ja) 2006-10-13 2014-05-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 胃酸分泌抑制作用を有するベンズイミダゾール化合物
EP1947099A1 (en) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
KR101522865B1 (ko) 2007-02-21 2015-05-26 시플라 리미티드 에소메프라졸 마그네슘 2수화물의 형태 a의 제조방법
US8492551B2 (en) * 2007-06-07 2013-07-23 Aurobindo Pharma. Ltd. Process for preparing an optically active proton pump inhibitor
CN101323609B (zh) * 2007-06-15 2013-05-01 成都福瑞生物工程有限公司 不对称氧化硫醚成亚砜合成对映体含量高的苯并咪唑衍生物的方法
US20100210848A1 (en) * 2007-10-03 2010-08-19 Ipca Laboratories Ltd. Process for optically active sulfoxide compounds
WO2009047775A2 (en) 2007-10-08 2009-04-16 Hetero Drugs Limited Polymorphs of esomeprazole salts
KR20100116165A (ko) 2007-10-12 2010-10-29 다케다 파마슈티칼스 노쓰 어메리카, 인코포레이티드 음식 섭취와 관계없이 위장 장애를 치료하는 방법
FR2925899B1 (fr) * 2007-12-27 2012-12-21 Sidem Pharma Sa Procede de preparation enantioselective de sulfoxydes.
CN101492459B (zh) * 2008-01-25 2011-04-27 山东轩竹医药科技有限公司 含烷氧乙酰基二氢异噁唑并吡啶化合物
CN101497603B (zh) * 2008-01-30 2012-11-07 山东轩竹医药科技有限公司 含有被烷氧烷胺氧基取代的吡啶的苯并咪唑衍生物
KR20100123758A (ko) 2008-03-10 2010-11-24 다케다 야쿠힌 고교 가부시키가이샤 벤즈이미다졸 화합물의 결정
WO2009117489A1 (en) * 2008-03-18 2009-09-24 Dr. Reddy's Laboratories Ltd. Dexlansoprazole process and polymorphs
CN101538264A (zh) * 2008-03-19 2009-09-23 中国科学院成都有机化学有限公司 手性亚砜类化合物的制备新方法
WO2009145368A1 (en) * 2008-05-27 2009-12-03 Sk Chemicals Co., Ltd. Improved preparing method of (s)-omeprazole from omeprazole racemate using optical resolution agent
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
WO2010039885A2 (en) * 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
EP2264024A1 (en) 2008-10-14 2010-12-22 LEK Pharmaceuticals d.d. Process for the preparation of enantiomerically enriched proton pump inhibitors
IT1391776B1 (it) 2008-11-18 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo
CZ200990A3 (cs) * 2009-02-16 2010-08-25 Zentiva, K.S. Zpusob výroby (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazolu
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
CZ2009172A3 (cs) * 2009-03-17 2010-09-29 Zentiva, K.S. Zpusob výroby (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazolu
WO2010150276A2 (en) * 2009-06-02 2010-12-29 Sun Pharmaceutical Industries Limited Process for preparing sulphoxide compounds
IT1395118B1 (it) 2009-07-29 2012-09-05 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
EP2499125B1 (en) 2009-11-12 2016-01-27 Hetero Research Foundation Process for the resolution of omeprazole
US20130197232A1 (en) 2010-01-29 2013-08-01 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
AU2011268774A1 (en) 2010-06-24 2013-01-17 Cipla Limited Salts and polymorphs of dexrabeprazole
CN101914090B (zh) * 2010-08-13 2013-03-20 埃斯特维华义制药有限公司 左旋奥美拉唑的制备方法
CN102558150B (zh) * 2010-12-31 2014-03-12 正大天晴药业集团股份有限公司 取代亚砜化合物的合成方法
CN102321071B (zh) * 2011-07-20 2013-01-23 江苏奥赛康药业股份有限公司 一种高纯度埃索美拉唑钠的工业化生产方法
CN102977076A (zh) * 2011-09-02 2013-03-20 扬子江药业集团上海海尼药业有限公司 一种右兰索拉唑的制备方法
CN102329302A (zh) * 2011-10-22 2012-01-25 刘强 一种埃索美拉唑及其盐的制备方法
CN102408412A (zh) * 2011-10-25 2012-04-11 广东华南药业集团有限公司 高对映体选择性制备（s）- 奥美拉唑的方法
CN102432412A (zh) * 2011-10-28 2012-05-02 成都欣捷高新技术开发有限公司 一种手性亚砜类质子泵抑制剂或其可药用盐的制备方法
KR101300950B1 (ko) * 2011-10-31 2013-08-27 르노삼성자동차 주식회사 전기자동차의 공기 흡입 장치
WO2013140120A1 (en) 2012-03-22 2013-09-26 Cipla Limited Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole
CN102633776B (zh) * 2012-03-28 2014-06-18 中山市仁合药业有限公司 一种埃索美拉唑及其钠盐的制备方法
CN102659763B (zh) * 2012-04-27 2014-01-22 南京优科生物医药研究有限公司 一种右旋兰索拉唑合成与纯化的方法
CN103044402B (zh) * 2012-12-31 2015-01-14 康普药业股份有限公司 埃索美拉唑钠合成生产方法
CN103113351B (zh) * 2013-03-08 2015-01-21 苏州特瑞药业有限公司 一种光学纯手性亚砜类化合物的制备方法
CN104177336A (zh) * 2013-05-28 2014-12-03 上海汇伦生命科技有限公司 一种对映选择性合成右兰索拉唑的方法
EP2933002A1 (en) 2014-04-11 2015-10-21 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of dabigatran and proton pump inhibitors
WO2015155307A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
EP2980086B1 (en) 2014-07-29 2016-06-15 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Efficient process for the preparation of esomeprazole (S)-binol complex
CN107428726B (zh) * 2014-12-26 2021-03-16 国立大学法人东京大学 光学活性的质子泵抑制剂化合物的制备方法
CN104610226A (zh) * 2014-12-31 2015-05-13 广东东阳光药业有限公司 一种右兰索拉唑的不对称氧化方法
ES2615637T3 (es) 2015-03-06 2017-06-07 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Procedimiento mejorado para la purificación óptica del esomeprazol
CN105218391B (zh) * 2015-07-09 2017-11-21 天津青松华药医药有限公司 L‑酒石酸单酯单酰胺类化合物
CN105218392B (zh) * 2015-07-09 2017-11-21 天津青松华药医药有限公司 D‑酒石酸单酯单酰胺类化合物
CN105968097B (zh) * 2016-05-17 2019-05-03 杭州华东医药集团新药研究院有限公司 左旋泮托拉唑的工业化生产方法
CN106083818A (zh) * 2016-06-08 2016-11-09 扬子江药业集团有限公司 一种高纯度埃索美拉唑钠的制备方法
CN106366070B (zh) * 2016-08-10 2019-06-11 上海万巷制药有限公司 一种高纯度埃索美拉唑钠的制备方法
CN106632248A (zh) * 2016-09-30 2017-05-10 青岛云天生物技术有限公司 一种左旋泮托拉唑钠的制备工艺
CN106632249A (zh) * 2016-09-30 2017-05-10 青岛云天生物技术有限公司 一种制备(s)‑泮托拉唑钠的方法
CN106866630B (zh) * 2017-04-01 2018-08-07 上海华源医药科技发展有限公司 一种右兰索拉唑的制备方法
CN110746428A (zh) * 2019-10-29 2020-02-04 株洲千金药业股份有限公司 一种r型手性亚砜类化合物的制备方法
CN110698482A (zh) * 2019-10-29 2020-01-17 株洲千金药业股份有限公司 一种s型手性亚砜类化合物的制备方法
CN113845510B (zh) * 2020-06-27 2025-02-18 鲁南制药集团股份有限公司 一种埃索美拉唑的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423970D0 (en) * 1994-11-28 1995-01-11 Astra Ab Oxidation
GB9423968D0 (en) * 1994-11-28 1995-01-11 Astra Ab Resolution

Also Published As

Publication number Publication date
TNSN95081A1 (fr) 1996-02-06
EP0773940A1 (en) 1997-05-21
IS4406A (is) 1996-12-27
KR100356252B1 (ko) 2002-11-18
SI0773940T2 (sl) 2011-02-28
SK4897A3 (en) 1997-08-06
DK0773940T3 (da) 2003-09-15
NO970153L (no) 1997-01-14
AR003443A1 (es) 1998-08-05
EP0773940B2 (en) 2010-11-17
CN1157614A (zh) 1997-08-20
HK1008331A1 (en) 1999-05-07
EG24534A (en) 2009-08-30
MA23611A1 (fr) 1996-04-01
CZ297987B6 (cs) 2007-05-16
PL318165A1 (en) 1997-05-26
IL114477A0 (en) 1995-11-27
HRP950401B1 (en) 2004-04-30
AU688074B2 (en) 1998-03-05
JPH10504290A (ja) 1998-04-28
CA2193994C (en) 2005-05-03
IS1772B (is) 2001-06-01
SK284059B6 (sk) 2004-09-08
NO970153D0 (no) 1997-01-14
FI117672B (sv) 2007-01-15
CA2193994A1 (en) 1996-02-01
YU47695A (sh) 1998-07-10
MY113180A (en) 2001-12-31
SA95160294B1 (ar) 2006-07-31
TR199500861A2 (tr) 1996-06-21
DK0773940T4 (da) 2011-02-07
SE9402510D0 (sv) 1994-07-15
WO1996002535A1 (en) 1996-02-01
ATE242233T1 (de) 2003-06-15
TW372971B (en) 1999-11-01
DZ1911A1 (fr) 2002-02-17
SE504459C2 (sv) 1997-02-17
CN1070489C (zh) 2001-09-05
RU2157806C2 (ru) 2000-10-20
EE03354B1 (et) 2001-02-15
UA47409C2 (uk) 2002-07-15
PT773940E (pt) 2003-10-31
IL114477A (en) 2001-07-24
FI970102A0 (sv) 1997-01-10
WO1996002535A8 (en) 1999-12-23
FI970102L (sv) 1997-01-10
NO312101B1 (no) 2002-03-18
MX9700358A (es) 1997-04-30
PL186342B1 (pl) 2003-12-31
HU226361B1 (en) 2008-09-29
JP3795917B2 (ja) 2006-07-12
US5948789A (en) 1999-09-07
YU49475B (sh) 2006-05-25
AU2994895A (en) 1996-02-16
DE69530987T3 (de) 2011-07-07
EP0773940B1 (en) 2003-06-04
HRP950401A2 (en) 1997-10-31
HUT76642A (en) 1997-10-28
KR970704731A (ko) 1997-09-06
ES2199998T3 (es) 2004-03-01
FI117830B (sv) 2007-03-15
DE69530987D1 (de) 2003-07-10
SI0773940T1 (en) 2004-02-29
SE9402510L (sv) 1996-01-16
ES2199998T5 (es) 2011-03-16
DE69530987T2 (de) 2004-05-19
BR9508292A (pt) 1997-12-23
CZ6497A3 (en) 1997-06-11
NZ289959A (en) 1998-01-26

Similar Documents

Publication Publication Date Title
HK1008331A1 (en) Process for synthesis of substituted sulphoxides
HU9603081D0 (en) Process for selective synthesis of sylil-alkyl-disulfides
EP0886638A4 (en) IMPROVED PROCESS FOR THE SYNTHESIS OF OLIGOMER COMPOUNDS
HUP9900110A3 (en) Novel process for the synthesis of omeprazole
IL144155A (en) Process for the synthesis of dioxolane derivatives
GB2272701B (en) Process for the synthesis of polyamides
IL129868A0 (en) Process for the synthesis of benzothiopenes
EP0508346A3 (en) Process for the enzymatic synthesis of 2-desoxy-beta-d-galactosides
ZA95694B (en) Novel derivatives of tetramethylcyclopropane
EG21612A (en) Process for preparing of naphtoqunone derivatives
EP0556630A3 (en) Process for the synthesis of exomethylenecephams
HUP9900923A3 (en) Process for the synthesis of vinyl-sulfenic acid derivatives
IL113555A0 (en) Process for the synthesis of haloalkylferrocenes
IL113596A0 (en) Large-scale process for azapirone synthesis
IL115848A0 (en) Production of triazoles
EG21037A (en) Process for the synthesis of benzathiophenes
AU7752391A (en) Process for direct synthesis of mordenites
HU9400973D0 (en) Process for producing of 2-halogen-pyridine derivatives
RU1833384C (ru) Cпocoб пoлучehия пpoизboдhыx cульфoлeha
GB2262281B (en) Process for the synthesis of cephams
ZA949875B (en) Process for the synthesis of 1-romo-2-fluoroethane
PL302380A1 (en) Novel derivative of pyrimidobenzodiazepin
HU9401151D0 (en) Process for preparation of supho-succinate-monoesters
HU212885B (en) Process for preparation of n-methoxy-acetyl-anilines
HU9402335D0 (en) Process for preparation of oxal-acetic-acid